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Sununary 
Interleukin 10 (IL-10) is released during the induction phase of contact sensitivity and was shown 
in prior functional studies to convert epidermal Langerhans cells (LC) from potent inducers of 
primary immune responses to specifically tolerizing cells in vitro. To investigate whether IL-10 
also subserves the function of a tolerizing agent in vivo ears of  BALB/c or C3H mice were injected 
intradermally with 1-2 pg of recombinant mouse (rm)IL-10 8 h before epicutaneous application 
of 3% trinitrochlorobenzene (TNCB; a contact allergen). As a control, mice were injected with 
phosphate-buffered saline or IL-10 plus neutralizing amounts of anti-IL-10 mAb. 5 d later, mice 
were challenged with 1% TNCB on contralateral ears and ear swelling response was measured 
24 h later. Whereas control-treated mice showed a normal ear swelling response to epicutaneous 
challenge (A mm  -2  =  25  _+  5), ear swelling response of IL-10-treated animals was significantly 
inhibited (A mm -2  =  3  _+  2).  Coinjection of IL-10-specific mAb together with traiL-10 
completely abrogated this effect. To differentiate  between a state of nonresponsiveness  and induction 
of tolerance by IL-10, mice initially treated with IL-10 and TNCB were resensitized with 3% 
TNCB in the absence of any treatment after 14 d of rest (group 1). Again mice were challenged 
5 d later and ear swelling responses were tested. Whereas control mice treated with allergen 
alone (group 2) showed a good swelling response (Amm -2  =  28  _+  6), IL-10-treated mice 
(group 1) showed a minimal response towards application of allergen (A mm -2  =  4  +  2). To 
show that anergy induction by IL-10 was antigen-specific, mice initially treated with IL-IO plus 
TNCB were exposed to 0.5% dinitrofluorobenzene (DNFB) 14 d later (group 1). After challenge 
with 0.1% DNFB, IL-10-treated  mice showed an ear swelling response (A mm -2  =  13  -+  3; 
group 1) similar to that of control mice only sensitized with DNFB (A mm -2 =  14  _+ 3; group 
3). In an attempt to show the induction of antigen-specific  tolerance in these mice in vitro, regional 
lymph nodes of mice initially treated with TNCB plus IL-10 (group 1) and control-treated mice 
(groups 2 and 3) were prepared and cultured in the presence of TNBS, dinitrobenzene sulfonate 
(DNBS), or medium to measure antigen-specific proliferation.  Lymph node cells from animals 
sequentially treated with IL-10 plus TNCB and afterwards DNFB in the absence of IL-10 (group 
1) showed a low, but significant proliferation  (,,,15,000 cpm) to DNBS, but only background 
proliferation (•3,000  cpm) to TNBS, or medium. In contrast, lymph node cells from animals 
treated with TNCB or DNFB in the absence  of IL-10 (groups 2 and 3) proliferated  to the sensitizing 
agent, but not control allergens. To elucidate the mechanism of action of IL-10, the epidermal 
cytokine pattern was analyzed  on the mRNA level  after injection of IL-10 or controls and application 
of allergen.  Injection  of IL-10 (but  not  controls)  significantly  impeded the  induction  of 
proinflammatory cytokines IL-lfl, tumor necrosis factor cr  and IL-lol. In aggregate our data 
indicate that in vivo application of IL-10 before allergen treatment induces antigen-specific  tolerance 
in mice and that IL-10 might act via inhibition of proinflammatory cytokines. 
I 
'L-10 was originally identified as a product of  Th2 cell dones 
. inhibiting the proliferation of Thl cell clones via down- 
regulation of IFN-~/and IL-2 production (1, 2). These effects 
are dependent on the presence of viable APCs and their ex- 
tent varies depending on the kind of APCs used (3). Initial 
studies performed with macrophages, B cells, or blood den- 
dritic cells showed a significant inhibitory influence of IL-10 
on the APC functions of macrophages only (4-6). In this 
system the inhibitory influence of IL-10 on the proliferation 
of  Thl cell clones was thought to be mediated  by downregu- 
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Volume  179  April 1994  1397-1402 lation of MHC  class  II molecules.  In addition,  De Waal 
Malefyt  et  al.  (14)  discussed  an  inhibitory influence on 
costimulatory molecules. They demonstrated that the inhi- 
bition of MHC class II molecules on human monocytes by 
IL-10 could be reversed by IL-4. The inhibitory effect on the 
proliferation of  T ceUs on the other hand remained unaffected 
(4). These findings were supported by studies of Ding et al. 
(5) who reported a profound effect of IL-10 on macrophage 
accessory functions in assay systems independent of MHC 
class II expression.  This group recently related the IL-10 effect 
on macrophages to an inhibition of B7 expression (7). 
Recently it was shown that IL-10 is also a product of acti- 
vated keratinocytes and is released during the induction phase 
of contact sensitivity (8). Further studies could define the 
effects of IL-10 on dendritic I.angerhans ceils (LC) as the APC 
in the epidermis (9). It was demonstrated that IL-10 inhibited 
the induction of proliferation of Thl ceil clones by freshly 
prepared LC. This effect was independent of Ag-processing 
and shown to be mediated via inhibition of a costimulatory 
signal on LC (but not B7 or interceUular adhesion molecule 
1 (ICAM-1) [9]). In fact LC pretreated with IL-10 were con- 
verted from specifically sensitizing to specifically  tolerizing 
APC in vitro. The present study was designed to demon- 
strate tolerizing effects of IL-10 in vivo. 
Materials and Methods 
Animals.  BALB/c  and C3H/HeN mice were purchased from 
the Zentralinstitut ffir Versuchstierhaltung (Hannover, Germany). 
They were used at 8-12 wk of age. 
Chemical Treatment.  Trinitrochlorobenzene (TNCB) was pur- 
chased from Polysciences, Inc. (Warrington,  FA), dinitrof{uoro- 
benzene (DNFB) was purchased from Sigma Chemical Co.  (St. 
Louis, MO).  Trinitrobenzenesulfonate (TNBS) and  dinitroben- 
zenesulfonate (DNBS) were purchased from Eastman Kodak Co. 
(Rochester, NY). For in vivo induction of  anergy mice were anesthe- 
tized and 1-2 #g of  recombinant mouse (rm)IL-10  (kindly provided 
by M. Howard and S. Menon, DNAX Research Institute,  Palo 
Alto, CA) or Ibl0 together with 30/zg of anti-Ibl0 mAb (Phar- 
Mingen, San Diego, CA), or PBS were injected intradermally with 
a 30-g needle into the ears of naive mice. 8 h hter, 5/~1 of 3% 
TNCB (dissolved in acetone) were applied over the injection sites 
taking special care not to spread the allergen. 5 d later ears were 
challenged with 1% TNCB and ear swelling responses were mea- 
sured 24 h later with an engineer's micrometer  (Oditest®). IL- 
l-treated mice were then given a rest of 14 d and then resensitized 
anew in the absence  of  any treatment as described  before (10). After 
a final rest of 14 d the same animals were exposed to 0.5% DNFB 
on 2 d consecutively and challenged with 0.1% DNFB 4 d later. 
Ear swelling responses were measured 24 h hter. Control groups 
were mice sensitized and chalhnged with TNCB or DNFB in the 
absence of any treatment,  or just challenged animals. All experi- 
ments were performed at least in triplicate with six mice per group. 
Lymph Node Proliferation  Assays.  Draining regional lymph nodes 
from animals treated with TNCB and Ibl0 as described above or 
control-treated animals were removed immediately after determi- 
nation of  swelling responses, mashed, and either pulsed with TNBS, 
or DNBS (water soluble analogues of DNCB and DNFB), or 
medium as described (11). Cells were then aliquoted at 2  x  10  s 
cells/well in 96-well  phtes (Becton Dickinson & Co., Oxnard, UK) 
and proliferation was determined by addition of 1 #Ci [SH]thymi- 
dine for the hst 12-16 h of the 96 h incubation. 
PCR and Liquid Hybridization.  EC suspensions were prepared 
as described  previously (12) and total epidermal RNA was extracted 
by RNAzol B (Paesel und Lorei, Frankfurt,  Germany) following 
the instructions of the manufacturer. PCR amplification was per- 
formed according to Saiki et al. (13)  with cycling  conditions chosen 
at 1 min at 95°C, 1.5 rain at 55°C,  and 2 rain at 72°C and 25 
cycles  using the Perkin Elmer RNA-PCR kit (Perkin-Elmer, Uber- 
lingen, Germany). Primers were designed according to published 
sequences and span one intron (10). Primer and RNA concentra- 
tions, as well as PCR cycles  were titrated to establish standard curves 
to document linearity and to permit quantitative analysis of signal 
strength.  5 lgl of amplified PCR product were hybridized to an 
excess of 32P-endlabeled probe as described (10). All probes con- 
sist of internal sequences of our specific PCR products. After hy- 
bridization, samples were loaded on 4% PAGE gels, dried, and an- 
toradiographed.  Omission of reverse transcriptase controlled for 
DNA contamination. 
Statistical Analysis.  A Student's t test was performed to docu- 
ment interpretability  of ear swelling responses. 
Results  and  Discussion 
Inhibition of  Priraary Sensitization by IL,  IO.  To demonstrate 
inhibition of sensitization in vivo, mice were anesthetized 
and injected with 1-2/~g traiL-10 in 50 #1 sterile PBS or 
controls. 8 h later ears were treated with 5/tl 3% TNCB 
above the injection site, taking special care not to spread the 
allergen. 5 d  later 1% TNCB was applied to contralateral 
ears and ear swelling was determined 24 h later with an en- 
gineer's micrometer (Fig. 1). Whereas control-treated mice 
(injected with PBS or IL-10 plus saturating amounts of neu- 
tralizing anti-IL-10 mAb) showed a good swelling (A mm -2 
=  25  _+  5) response towards allergen treatment, animals in- 
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Figure  1.  Inhibition of primary sensitization  in mice by IL-10. Mice 
were injected intradermally  into the ears with 2/~g rmlL-10 (I]--10 + 
TNCB), PBS (PBS +  TNCB), or 2/zg ID10 plus 20/~g of anti-IL-10 
mAb (Ibl0 + TNCB + anti-IL-10)  and painted  with 3% TNCB above 
the injection  site  8 h later, or were  only treated  with 3% TNCB (TNCB) 
without prior injection. 5 d hter mice  were challenged  with 1% TNCB 
applied to contrahteral  ears and ear swelling  was measured  24 h later  with 
an engineer's micrometer. Mice only painted with 1% TNCB on day 5 
served as control for nonspecific  inflammatory  edema  caused by chemica~ 
painting (challenge  only),  x-axis shows differences  in ear thickness  before 
and after challenge (A mm-2). 
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reaction (Amm  -z  =  3  +  2, p <0.001; Fig.  1) showing a 
state of nonresponsiveness. The challenge only group reflects 
the amount of nonspecific swelling caused by allergen appli- 
cation alone. 
Injection of IL-10 8 h before application of allergen seemed 
to be crucial for the induction of nonresponsiveness as time 
course experiments demonstrated that injection of IL-10 at 
the time of TNCB painting or later failed to induce such 
an effect. Also injection of IL-10 12 h or later before the ap- 
plication of TNCB was without effect (data not shown). Fur- 
thermore, comparatively high doses of IL-10 were needed to 
see an inhibition of ear swelling responses with doses below 
0.5/~g being without effect. Injection of 2/~g of IL-10 proved 
to be most effective in the induction of IL-10-mediated non- 
responsiveness. 
In addition, analysis of MHC class II expression of LC after 
IL-10 injection and TNCB treatment on epidermal sheets 
demonstrated an upregulation of those molecules after hapten 
application showing no difference to LC on epidermal sheets 
treated with contact allergen  alone. 
Induction of  Hapten-specific  Tolerance  by IL-IO.  To investigate 
whether hapten-specific tolerance was induced in IL-10 plus 
allergen-treated mice, these animals were resensitized  after 
a period of 14 d with 3% TNCB in the absence of any treat- 
ment and challenged with TNCB as described.  Indeed the 
ear swelling response of IL-10-pretreated mice remained low 
(A mm-2 =  2  __  2). In contrast, mice treated with allergen 
only (TNCB) responded normally (Amm -2  =  22  _+  5, 
/~ <0.001,  Fig.  2). 
To exclude the possibility that allergen plus IL-10-pretreated 
mice were nonresponsive to any given stimulus, animals were 
resensitized  with a different contact allergen  (DNFB)  14 d 
later  in  the  absence  of any  treatment.  TNCB  plus  IL- 
10-pretreated mice behaved  like normal controls in their 
swelling response towards DNFB (A ram-z  =  13  _+  3 vs. 
A mm-2 =  14 _+ 2, p <0.001) demonstrating the capability 
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Figure 2.  ID10 induces long-hsting anergy in mice. Mice initially treated 
with TNCB plus Ibl0 (TNCB +  Ibl0 pretreatment)  as described in Fig. 
1 as well as control mice (TNCB) were sensitized  14 d later  with 3% 
TNCB. Contralateral  ears were painted  with 1% TNCB 5 d later and 
ear swelling responses were measured after an additional 24 h. x-axis shows 
A ram-2. 
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Figure  3.  Induction  of  tolerance  by  IL-10 is  hapten-specific;  Mice 
pretreated with TNCB plus Ibl0 as described in Fig. 1 and resensitized 
14 d later with TNCB as described in Fig. 2 (ID10 pretreatment)  as well 
as untreated  controls  (DNFB) were exposed to 0.5% DNFB on 2 d con- 
secutively. Contralateral  ears were treated with 0.1% DNFB 4 d hter and 
ear swelling response measured after an additional 24 h or challenged only. 
x-axis shows A mra-2. 
of these animals to launch immunological  responses in prin- 
cipal (Fig.  3). 
Hapten-specific  Lymph Node Proliferation  Is Severely Impeded 
in IL-lO-treatedMic~  Draining lymph nodes from mice made 
anergic with TNCB plus I1,-10  pretreatment and resensitized 
sequentially  with TNCB and (14 d later) DNFB (tested by 
ear swelling responses), or lymph node ceils from mice treated 
only with TNCB or DNFB were prepared and cultured in 
96-well  plates for 4 d in the presence  of TNBS or DNBS 
or medium. Proliferation was detected by incorporation of 
[3H]thymidine during the last  12-16  h. Lymph node ceils 
from only TNCB- or DNFB-sensitized mice responded well 
('~14,000 cpm) towards the respective soluble antigen, but 
did not show cross-reactivity  to the other allergen  and did 
not proliferate  to  medium alone ('~3,000  cpm, data not 
shown). Lymph node cells derived from animals treated with 
TNCB plus IL-10 and resensitized with TNCB and DNFB 
proliferated only to DNBS, but not TNBS (Fig. 4) or medium 
(not shown). Addition of 100 U/m1 of rIL-2 to the TNCB 
plus IL-10-pretreated TNBS group restored the proliferating 
capacity of these ceils excluding cell death. Our data indicate 
the induction of hapten-specific tolerance in lymph node cells 
derived from allergen  plus IL-10-treated mice. 
Inhibition of  Epidermal Cytokines by IL-IO.  As other inves- 
tigators have demonstrated an inhibitory effect of IL-10 on 
monocyte-derived  cytokines (14), we wondered whether IL- 
10-mediated induction of tolerance might be mediated by 
inhibitory effects on epidermal cytokines known to be essen- 
tial for the induction of primary immune responses in skin 
(11). Therefore 1-2 #g of rmIL-10 or IL-10 together with 
anti-IL-I0 mAb were injected into the ears of anesthetized 
mice 8 h before epicutaneous application of allergen  as de- 
scribed above. 4 h after application of allergen EC suspen- 
sions were prepared and total epidermal RNA was extracted 
as described in the Materials and Methods section. This pro- 
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Figure  4.  Inhibition ofhapten specific lymph node proliferation by IL- 
10. Draining lymph nodes from animals either treated with TNCB plus 
IL-10  or control-treated  were prepared and incubated with DNBS, TNBS, 
or TNBS plus 100U rI~2 for 4 d. 1 #Ci [3H]thymidine  was added for 
the last 12-16 h to measure proliferation. Groups are: TNCB-treated animals 
stimulated with TNBS in vitro (TNCB/TNBS); DNFB-treated animals 
treated with DNBS in vitro (DNFB/DNBS); TNCB-treated animals stimu- 
hted with DNBS in vitro (TNCB/DNBS); DNFB-treated animals stimu- 
lated with TNBS in vitro (DNFB/TNBS); animals pretreated with II.-10 
and TNCB and r-=ensitized sequentially with TNCB and (14 d later) DNFB 
and stimulated with TNBS (IL-10 +  TNCB  +  DNFB/TNBS); animals 
pretreated with ID10 and TNCB and resemitized sequentially with TNCB 
and DNFB stimulated with DNBS (IL-10 +  TNCB  +  DNFB/DNBS); 
and animals  pretreated with IL-10 and TNCB  and resensitized  sequen- 
tially with TNCB and DNFB stimulated with TNBS plus 100 U  rlL-2 
(IL-10 +  TNCB  +  DNFB/IL-2). Background proliferation varied between 
3143  +  324  and 3321  +  429  cpm. 
Figure  5.  I1--10  downregulates epidermal cytokines.  3%  TNCB  was 
applied to the ears of BALB/c mice 8 h after the injection of 1, nothing; 
2, 2/zg IL-10  plus 30/tg anti-IL.10 mAb, or 3, 2/tg ID10 and total epidermal 
RNA was extracted 4 h later as described.  RNA was analyzed by quan- 
titative PCR using primers for IDI~, Ibl,v, TNF-o~, or ~-actin controls, 
and subjected to analysis by PAGE, dried, and autoradiographed. Injection 
of PBS alone did not result in significant  signal induction (not shown). 
cedure was followed by a quantitative  reverse transcriptase 
PCR using primers for IL-1B, IL-lot, TNF-c~, and ~-actin 
controls.  Indeed a significant inhibition of mRNA induc- 
tion could be observed for all cytokines tested after pretreat- 
ment with IL-10, whereas ~-actin controls remained unaffected 
(Fig. 5). In this regard the downregulation of IL-lfl by IL- 
10 seems to be of paramount importance. Prior studies have 
shown that the induction of IL-1B in epidermal LC is essen- 
tial for inducing primary immune responses in skin (11). IL- 
18 is the first cytokine (within 15 min of hapten application) 
to be induced after application  of allergen (not irritant or 
tolerogen). It was also shown to be capable of triggering the 
whole cascade of cytokines characteristic for the induction 
phase of contact sensitivity, as well as causing changes in LC 
morphology, MHC class II expression, and density closely 
resembling those caused by allergen in vivo. In addition, in- 
jection of anti-lL-1/~ mAb before allergen  application prevented 
sensitization in mice (11), emphasizing the essential role of 
IL-1B as an important costimulator in primary immune re- 
sponses in skin. The inhibition of this important molecule 
by IL-10 might be one of the mechanisms of IL-10 action 
in skin. 
The production of IL-10 by epidermal keratinocytes during 
the induction phase of contact sensitivity and the rather late 
upregnlation of this cytokine compared with others was shown 
some time ago (8). Further studies characterized the effect 
of IL-10 in skin as an inhibition of LC APC function (9). 
It was demonstrated that IL-10 inhibited the proliferation 
of Thl  call  clones  induced by  IL-10-pretreated  LC  and 
prevented the upregulation of costimulatory molecules on 
these ceils. Therefore,  IL-10 converted LC from potent in- 
ducers of primary immune responses to specifically  tolerizing 
calls in vitro (9). In this study we demonstrate that local in- 
jection of IL-10 before epicutaneous application of allergen 
also induces hapten-specific tolerance in vivo. We further- 
more demonstrate an effect of IL-10 on the local cytokine 
milieu of the epidermis during the induction of a primary 
immune response. In this regard we show that IL-10 inhibits 
production ofmRNA signals for IL-1/3, IL-lcx, and TNF-ot. 
The observation that the epidermal cytokine pattern of the 
epidermis  is disturbed by IL-10 is of spedal interest  to us 
as we demonstrated before that the early induction phase of 
contact sensitivity  is characterized by a rather distinct and 
specific  pattern of epidermal cytokines only induced after ap- 
plication of allergen, not tolerogen or irritant application (11). 
Among all cytokines assessed especially keratinocyte-derived 
TNF-c~ (15) and IL-6 (16), as well as LC-derived IL-I~ (11, 
17) seem to be important. Our own group demonstrated that 
IL-lfl  production by epidermal  LC is preceding all other 
cytokines tested. In fact, IL-lfl alone is sufficient to induce 
the whole cascade of allergen-specific cytokines and a mono- 
clonal anti-IL-1/~ antibody injected into the skin before ap- 
plication of allergen completdy prevented epicutaneous sen- 
sitization (11). This demonstrates  that IL-1B production by 
LC is indeed essential for the induction of primary immune 
responses in skin (11). Therefore an inhibition of LC-derived 
IL1B by IL-10 might help explain the mechanism of toler- 
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tion of IL-lfl and the following release of proinflammatory 
cytokines by keratinocytes is needed for the upregnlation of 
certain costimulatory molecules on LIE or that these cytokines 
might serve as costimulators themselves as has been described 
for IL-1 in macrophage systems (18). This is of special im- 
portance as Schuler and Steinman (19) have demonstrated  be- 
fore that resident LC in the epidermis are rather immature 
with regard to their capability to induce T cell proliferation 
as compared with dendritic cells derived from lymph node, 
blood, or spleen (19-21). This is at least partially due to a 
lack of costimulatory signals on resident LC that need to ac- 
quire these molecules  during their migration to regional lymph 
nodes. As absence of  costimulation in the presence of antigen- 
presentation leads to T cell anergy (22), LC leaving the skin 
under the influence of 1L-10 and incapable of upregulating 
those costimulatory molecules might serve as tolerizing APC, 
thereby limiting the amount of specifically  sensitized T cells. 
This might serve as a counterregnlatory mechanism in pri- 
mary immune responses in skin to minimize tissue damage. 
This theory is supported by data generated by Ding et al. 
(5)  who  demonstrated in  an  MHC  class II-independent 
proliferation assay that IL-10 inhibited a costimulatory mol- 
ecule on macrophages.  In further studies the costimulator 
was shown to be B7 (7). Although B7 expression does not 
seem to be affected on LC, our own data dearly demonstrate 
that some other costimulatory molecule is target of IL-10 
action on LC (9). 
Recently Rivas and Uilrich (23) showed that intraperitoneal 
injection of high amounts of supernatant derived from UV- 
irradiated KC suppressed  delayed-type  hypersensitivity (DTH) 
responses in mice as assessed  by footpad swelling. The active 
compound in the supernatants was shown to be IL-10 as an 
IL-10-specific mAb completdy reversed the effect. Our own 
attempts to induce suppression of contact allergy induction 
by intraperitoneal injection of IL-10 were rather unsuccessful. 
Possible explanations for this might be that the amounts of 
IL-10  reaching the  application  site  of the  allergen  were 
insufl~dent. Although Rivas and Ullrich (23) did not exactly 
quantify the amount of IL-10 that was injected in their study, 
Powrie et al. (24), in a very recent report, needed doses in 
between 20 and 50/~g of purified IL-10 injected i.p. to ob- 
serve an effect on DTH reactions. This exceeds the amount 
that is available to us by far. Our own attempts to block DTH 
reactions using the system of Rivas and UUrich (23) with 
doses of 1-2 #g IL-10 showed no effect on footpad swelling 
or epidermal mRNA expression. Alternatively it is possible 
that the special cellular milieu of the epidermis is necessary 
for the induction of hapten-specific tolerance in our system. 
Our studies also fit with data recently published by Hsieh 
et al. (25). These authors investigated the capacity of  various 
cytokines to modulate Thl or Th2 effector cells when in- 
cluded during the primary stimulation with matched APCs. 
Using naive T cells derived from an MHC class II-restricted, 
ovalbumin-specific, transgenic T cell receptor mouse, these 
authors demonstrated that in the absence of additions, a Th0 
phenotype producing low amounts of  IFN-3: and IL4 resulted 
in primary stimulation cultures. In contrast, addition of IL-4 
to primary stimulation cultures resulted in a complete polar- 
ization to Th2 ceils. This effect was independent of the APCs 
used to initiate T  cells. On the contrary,  neutralization  of 
endogenous IL-10 during T cell activation markedly  increased 
IFN-'y production and reduced IL-4 and IL-5 production, 
twisting the immune response towards Thl development. 
Although IL-10 by itself did not seem to induce Th2 cell 
development directly, it might strongly direct development 
towards the Th2 phenotype  by downregulating IFN-'y levels. 
This effect of IL-10 is dependent on the APC used and sup- 
ports the notion that APCs together with the local cytokine 
milieu might determine the phenotype of the responding T 
cell. 
The exact mechanism by which IL-10 induces hapten- 
specific tolerance in our system remains speculative. Although 
our in vitro and in vivo data seem to exclude an effect of 
IL-10 on LC MHC class II expression and although our in 
vitro data clearly demonstrate that IL-10 converts LC to tolero- 
genie APCs by inhibiting the upregnlation of costimulatory 
molecules it remains to be proven whether this is the mecha- 
nism of IL-10 action in our in vivo system. As a solution 
for  this  problem  more  information  about  the  kind  of 
costimulatory signal affected by IL-10 needs to be collected. 
Thus far all attempts to characterize the IL-10 effect on the 
molecular level were without success as neither expression 
of B7 nor heat-stable antigen or ICAM-1 seem to be affected 
(9). Neverthdess our studies open up to a whole new spec- 
trum of  possible clinical applications of IL-10 in humans and 
it will be the goal of future studies to determine the molec- 
ular details of IL-10 effects in skin. 
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